CIK 0001359931
- Non-accelerated filer
- Smaller reporting company
Protara Therapeutics, Inc.
Sign in to watch- Ticker
- TARA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 204580525
- Phone
- +1 646-844-0337
- Business address
- 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 31 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-30 | Flynn James E Director | Sale | −110,557 | $1.75 | $193K | 0 |
| 2017-11-15 | NOYES TIMOTHY P President and CEO | Returned to the company | −5,650 | $1.70 | $10K | 28,742 |
| 2017-11-14 | NOYES TIMOTHY P President and CEO | Returned to the company | −4,350 | $1.69 | $7K | 34,392 |
| 2017-11-14 | Eldridge, George Arthur Sr VP, CFO, Treasr, Asst Secy | Purchase | +295 | $1.69 | $499 | 1,545 |
| 2017-11-14 | BOHLIN GAREN G Director | Grant or award | +3,812 | $1.89 | $7K | 53,312 |
| 2017-11-13 | BOHLIN GAREN G Director | Grant or award | +25,700 | $1.92 | $49K | 49,500 |
| 2017-11-10 | BOHLIN GAREN G Director | Grant or award | +23,800 | $1.96 | $47K | 23,800 |
| 2017-10-16 | NOYES TIMOTHY P President and CEO | Returned to the company | −10,000 | $2.31 | $23K | 38,742 |
| 2017-09-15 | NOYES TIMOTHY P President and CEO | Returned to the company | −5,146 | $1.48 | $8K | 48,742 |
| 2017-09-14 | NOYES TIMOTHY P President and CEO | Returned to the company | −4,854 | $1.45 | $7K | 53,888 |
| 2017-08-02 | LEFF JONATHAN S Director | Grant or award · Stock Option (Right to Buy) | +13,333 | 13,333 | ||
| 2017-08-02 | Flynn James E Director | Grant or award · Stock Option (Right to Buy) | +13,333 | 13,333 | ||
| 2017-06-30 | Toner E. Scott Senior VP of Marketing | Grant or award | −8,718 | $1.30 | $11K | 8,853 |
| 2017-06-30 | Kowalsky Matthew Paul VP, Legal and Secretary | Grant or award | +10,000 | $1.30 | $13K | 13,097 |
| 2017-06-30 | Eldridge, George Arthur Sr VP, CFO, Treasr, Asst Secy | Grant or award | +10,000 | $1.30 | $13K | 12,750 |
| 2017-06-30 | Burke Steven Keith SVP and Chief Medical Officer | Grant or award | −10,000 | $1.30 | $13K | 105,535 |
| 2017-06-22 | TVM Life Science Ventures VI GmbH & Co KG Director | Purchase · Series A Convertible Preferred Stock | +372 | $1,000.00 | $372K | 500 |
| 2017-06-22 | Freund John Gordon Director | Purchase · Series A Convertible Preferred Stock | +1,054 | $1,000.00 | $1.1M | 1,054 |
| 2017-06-22 | Haines Timothy Director | Purchase · Series A Convertible Preferred Stock | +2,526 | $1,000.00 | $2.5M | 2,526 |
| 2017-06-22 | Abingworth LLP 10% owner | Purchase · Series A Convertible Preferred Stock | +2,526 | $1,000.00 | $2.5M | 2,526 |
Page 21 of 24 · 473 trades